The Lancet thelancet.com

[Articles] The effects of government-led cash transfer programmes on behavioural and health determinants of mortality: a difference-in-differences study

thelancet.com·27w

[Comment] Why cash transfers matter for global health—now more than ever

thelancet.com·27w

[Articles] The effects of government-led cash transfer programmes on behavioural and health determinants of mortality: a difference-in-differences study

thelancet.com·27w

[Articles] Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an indiv...

thelancet.com·27w

[Articles] Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an indiv...

thelancet.com·27w

[Comment] Complete revascularisation in patients with acute myocardial infarction

thelancet.com·27w

[Comment] Kidney disease must be counted everywhere

thelancet.com·27w

[Comment] Augmenting nephroprotection: balcinrenone plus dapagliflozin in chronic kidney disease

thelancet.com·27w

[Comment] New light on the activators of factor XI in venous thromboembolism

thelancet.com·27w

[Articles] Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomise...

thelancet.com·27w

[Articles] Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, o...

thelancet.com·27w

[Articles] Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomise...

thelancet.com·27w

[Comment] Augmenting nephroprotection: balcinrenone plus dapagliflozin in chronic kidney disease

thelancet.com·27w

[Comment] New light on the activators of factor XI in venous thromboembolism

thelancet.com·27w

[Articles] Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, o...

thelancet.com·27w

[Articles] Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for th...

thelancet.com·28w

[Comment] Kidney disease must be counted everywhere

thelancet.com·28w

[Hypothesis] Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?

thelancet.com·28w

[Comment] Selective amylin receptor agonism: promise beyond incretins

thelancet.com·28w

[Hypothesis] Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?

thelancet.com·28w

Log in to enable infinite scrolling